Blockade of testicular and adrenal androgens in prostate cancer treatment.
about
Structures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor bindingQuality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequencesIntratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Methoxychalcone inhibitors of androgen receptor translocation and function.Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor modelsMinireview: Androgen metabolism in castration-resistant prostate cancer.Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.PSA screening for prostate cancer: why so much controversy?Mechanisms of androgen receptor activation in castration-resistant prostate cancerThe 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.Management of cancer treatment-induced bone loss.Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers.In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer.Androgen synthesis in prostate cancer: do all roads lead to Rome?CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasionAccelerated crossing of fitness valleys through division of labor and cheating in asexual populations.Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.[Androgen receptor variants in prostate cancer].Biological activity of pyrazole and imidazole-dehydroepiandrosterone derivatives on the activity of 17β-hydroxysteroid dehydrogenase.Resistance to Hormonal Therapy in Prostate Cancer.Testosterone and androstanediol glucuronide among men in NHANES III.Prostate cancer-from steroid transformations to clinical translation
P2860
Q27700118-497AA2A7-569D-40A7-A028-01D1A0E83ABEQ28385758-8C3838B9-D7F8-41B0-8D28-17DED09414D5Q33701389-EF9BCEFC-D9B3-4A78-BBF7-F4FF3ABACC57Q34283623-59FCCDDE-607A-4800-99D9-8EB6265E7172Q34294888-1DDDD0AA-5B6B-494E-B35B-DE29315E76CEQ35841689-6FB8C8E7-CAAF-4F35-BAF1-24CB4947FAE3Q36275656-AEE87B9A-A739-4499-9DA0-C2FB604B6248Q36789277-549C15AD-36BA-4039-9DDA-7DA31558D189Q37270472-F2A0A2A5-5D60-41E1-A3EF-EF53A5B9D8F1Q37436987-5646EEEE-B38D-4751-90E2-F5407E11F688Q37628940-881B2BEF-E2F1-46C6-97E3-011EB3A7F487Q37953805-E2F892C7-07F4-4C4B-9834-86137B60F90FQ38090917-10B6D64D-27F2-412C-9409-F4FE87A848A6Q38243217-95EBE0EF-5A25-49A1-AF10-869A058110D6Q38979373-288C79E2-4C87-41E2-A862-13A574035854Q38996973-EF085041-49FB-4719-8373-901CB2FEE30AQ39002780-E445362E-D885-4734-94C4-292CB9782C8FQ41593121-A513353A-EDFF-45C7-8465-62AC9CDCEB24Q41873155-AB74E0E7-1F98-4EA8-B497-5E1AEAB8AD34Q42054793-ACA7A8AE-837C-413B-A54A-56328CC046F0Q47696958-18089A8F-11DE-4920-B21E-F3CD1CBFB2E5Q49845725-D1E8550C-9B6E-4993-8E20-48719C6C1D6BQ51744501-94B93A97-9480-49F6-B900-A55D7A6630BBQ53393993-991F1378-5C83-421A-86AF-A1FCA0851B14Q55259124-B4D47972-7D2A-45A7-B56B-98A5AA68C11FQ57132840-2E7A6B00-CACD-4438-A4C6-FA6677FA3731
P2860
Blockade of testicular and adrenal androgens in prostate cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@en
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@nl
type
label
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@en
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@nl
prefLabel
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@en
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@nl
P2860
P356
P1476
Blockade of testicular and adrenal androgens in prostate cancer treatment.
@en
P2093
Fernand Labrie
P2860
P2888
P356
10.1038/NRUROL.2010.231
P407
P577
2011-01-18T00:00:00Z